COMP <GO>
BIO vs ABBV // FORWARD P/E MULTIPLE
Bio-Rad Laboratories Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BIO 3
— ABBV 10
▲ FORWARD P/E MULTIPLE LEADER: BIO
LAST: $384.40 (-0.19%) • MKT CAP: $10.28B
forward-pe
12.6x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | 70.20% | -18.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.50% | 29.00% | -28.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 60.4x | 33.3x | +27.10 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | 3.47% | +0.17 | BIO | /fcf-yield <GO> |
| Operating Margin | 1.80% | 24.60% | -22.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 29.40% | 6.90% | +22.50 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | 8.60% | -7.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.59 | 5.33 | -1.74 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.0 | 65.1 | -6.10 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.15 | -0.11 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 12.6x | 113.1x | -100.50 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.28B | $513.86B | -$503.58B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | ABBV REV | BIO GROSS % | ABBV GROSS % | BIO FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $61.16B | 51.9% | 70.2% | $374.6M | $17.82B |
| FY 2024 | $2.57B | $56.33B | 53.7% | 70.0% | $289.6M | $17.83B |
| FY 2023 | $2.67B | $54.32B | — | — | $254.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
ABBV // BETA 1.15